These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 7590764)
1. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Snelling L; Miyamoto CT; Bender H; Brady LW; Steplewski Z; Class R; Emrich J; Rackover MA Hybridoma; 1995 Apr; 14(2):111-4. PubMed ID: 7590764 [TBL] [Abstract][Full Text] [Related]
2. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Brady LW; Miyamoto C; Woo DV; Rackover M; Emrich J; Bender H; Dadparvar S; Steplewski Z; Koprowski H; Black P Int J Radiat Oncol Biol Phys; 1992; 22(1):225-30. PubMed ID: 1309204 [TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Quang TS; Brady LW Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):972-5. PubMed ID: 14967458 [TBL] [Abstract][Full Text] [Related]
4. Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilot study. Brady LW; Markoe AM; Woo DV; Rackover MA; Koprowski H; Steplewski Z; Peyster RG J Neurosurg Sci; 1990; 34(3-4):243-9. PubMed ID: 1965903 [TBL] [Abstract][Full Text] [Related]
5. The use of epidermal growth factor receptor-425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of patients with high grade gliomas of the brain. Miyamoto CT; Brady LW; Rackover MA; Emrich J; Class R; Bender H; Micaily B; Steplewski Z Recent Results Cancer Res; 1996; 141():183-92. PubMed ID: 8722428 [No Abstract] [Full Text] [Related]
6. A new treatment for high grade gliomas of the brain. Brady LW Bull Mem Acad R Med Belg; 1998; 153(5-6):255-61; discussion 261-2. PubMed ID: 9988932 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy. Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493 [TBL] [Abstract][Full Text] [Related]
8. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Emrich JG; Brady LW; Quang TS; Class R; Miyamoto C; Black P; Rodeck U Am J Clin Oncol; 2002 Dec; 25(6):541-6. PubMed ID: 12477994 [TBL] [Abstract][Full Text] [Related]
9. Radiotherapy in supratentorial gliomas. A study of 821 cases. Heesters M; Molenaar W; Go GK Strahlenther Onkol; 2003 Sep; 179(9):606-14. PubMed ID: 14628126 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results. Ogawa K; Ishiuchi S; Inoue O; Yoshii Y; Saito A; Watanabe T; Iraha S; Toita T; Kakinohana Y; Ariga T; Kasuya G; Murayama S Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):732-8. PubMed ID: 21420247 [TBL] [Abstract][Full Text] [Related]
11. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Wygoda Z; Kula D; Bierzyńska-Macyszyn G; Larysz D; Jarzab M; Właszczuk P; Bazowski P; Wojtacha M; Rudnik A; Stepień T; Kaspera W; Etmańska A; Składowski K; Tarnawski R; Kokocińska D; Jarzab B Hybridoma (Larchmt); 2006 Jun; 25(3):125-32. PubMed ID: 16796458 [TBL] [Abstract][Full Text] [Related]
12. Interstitial iodine 125 and concomitant cisplatin followed by hyperfractionated external beam irradiation for malignant supratentorial glioma. Preliminary experience at the University of Tennessee, Memphis. Fontanesi J; Clark WC; Weir A; Barry A; Kumar P; Miller A; Eddy T; Tai D; Kun LE Am J Clin Oncol; 1993 Oct; 16(5):412-7. PubMed ID: 8213624 [TBL] [Abstract][Full Text] [Related]
13. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120 [TBL] [Abstract][Full Text] [Related]
14. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257 [TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)]. Afra D; Sipos L; Vitanovics D Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942 [TBL] [Abstract][Full Text] [Related]
16. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. Grossman SA; O'Neill A; Grunnet M; Mehta M; Pearlman JL; Wagner H; Gilbert M; Newton HB; Hellman R; J Clin Oncol; 2003 Apr; 21(8):1485-91. PubMed ID: 12697871 [TBL] [Abstract][Full Text] [Related]
17. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Fukushima T; Yamamoto M; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M Anticancer Res; 1998; 18(5D):3965-70. PubMed ID: 9854511 [TBL] [Abstract][Full Text] [Related]